The Science Behind Lactoferrin.

How to read this page

Not all evidence carries the same weight. A double-blind randomised controlled trial in 500 people tells you something a laboratory experiment cannot, and a laboratory experiment can reveal a mechanism no clinical trial is designed to see. Both matter, and they answer different questions.

So every section below carries a label describing the kind of evidence behind it, letting you see at a glance where the science is settled and where it is still developing.

Which lactoferrin this evidence applies to

This is an important distinction, and it is about to become more important still. Every study summarised on this page used bovine lactoferrin purified from cow's milk. That is the form with roughly seven decades of research behind it, the form used in the meta-analyses and randomised trials cited throughout, and the form we make.

A new generation of lactoferrin is now reaching the market, produced not from milk but by precision fermentation, in which yeast or fungi are engineered to express the protein. These include bioidentical human lactoferrin and fermentation-derived bovine lactoferrin. They are genuinely interesting, and some of the early work is encouraging. But their clinical evidence base is a small fraction of the one below, and the two should not be confused.

Why the evidence does not simply transfer

A protein is more than its amino acid sequence. Lactoferrin is a glycoprotein, and the sugar chains attached to it are added by the organism that produces it. A yeast glycosylates differently from a mammary gland. Those differences can affect stability, how the protein resists digestion, how receptors recognise it and how the immune system reads it. Human and bovine lactoferrin are also only about 69% identical in sequence to begin with, and in several laboratory comparisons the bovine form has been the more potent of the two.

So results obtained with milk-derived bovine lactoferrin cannot be assumed to hold for a fermentation-derived protein, in either direction. Each form has to earn its own evidence. That is not a criticism of the newer products, it is simply how the science works, and independent safety reviews have made a related point: reviewers noted that the immunogenicity and alloimmunisation potential of recombinant human lactoferrin had not been formally evaluated for a long period, a gap that trials published from 2024 onward have only recently begun to address.

Findings at a glance

A summary of what the human research shows across each health area, the doses studied, and the strength of the evidence behind it. Each row links to the full discussion.

These are summaries of published research on lactoferrin as a substance. They are not claims about the effects of any Lactoferrin Co. product. Individual results vary, and no dietary supplement is intended to diagnose, treat, cure or prevent any disease.

What lactoferrin is, and what makes it unusual

Lactoferrin is an iron-binding glycoprotein of the transferrin family, first isolated from bovine milk in 1939. It is produced by the mammary gland and by the mucosal surfaces lining the gut, airways, eyes and urinary tract, and it is stored in the granules of neutrophils, the first white blood cells to arrive at a site of infection. That distribution is the clearest signal of what it does: lactoferrin is positioned wherever the body meets the outside world.

The structure explains the function

A single lactoferrin molecule folds into two symmetrical lobes, each containing one high-affinity iron-binding site. Its affinity for iron is roughly 300 times that of transferrin, the protein that transports iron in blood, and it holds onto iron across a wide pH range, including the acidic conditions found at sites of inflammation, where other iron-binding proteins release their cargo.

This produces a dual character that little else in nutrition shares. In its iron-free form (apolactoferrin) it is an avid iron scavenger. Once loaded (holo-lactoferrin) its three-dimensional structure becomes measurably more stable and more resistant to digestive breakdown. Most commercially available bovine lactoferrin is around 10–20% iron-saturated, largely in the apo form, and therefore retaining most of its iron-binding capacity.

Lactoferricin: the active fragment

When lactoferrin meets pepsin in the stomach, part of its N-terminal region is cleaved off as a 25-amino-acid peptide called lactoferricin B. This fragment is strongly positively charged, folds into an amphipathic β-sheet, and is more potent as a direct antimicrobial than the parent protein. It works by a mechanism entirely separate from iron binding: it is drawn to the negatively charged surfaces of bacterial membranes and disrupts them.

This is a genuinely elegant piece of biology. Digestion does not simply destroy lactoferrin: for part of the molecule, digestion is what activates it.

How cells recognise it

Lactoferrin is not merely a passive iron sponge. Human cells carry specific receptors that bind it and trigger signalling: intelectin-1 on intestinal epithelial cells, which mediates uptake and activates MAPK signalling pathways; LRP1, involved in cellular uptake and in the lipolysis pathway relevant to the metabolic research below; and TLR4, a central receptor in innate immune signalling. Blocking intelectin-1 experimentally prevents both lactoferrin entry and the downstream signalling, confirming these are genuine receptor-mediated effects.

For a fuller treatment of these pathways, see our guide to how lactoferrin works in the body, or start with what lactoferrin is: the complete guide.

This is the first question any serious reader should ask about an orally consumed protein, and it has been measured directly in people rather than estimated.

Two things follow. First, meaningful quantities of intact lactoferrin do reach the intestine after oral intake, since the protein is unusually resistant to gastric degradation for its size. Second, the portion that is cleaved yields lactoferricin, which carries antimicrobial activity of its own. Neither fraction is wasted.

Iron is where lactoferrin research began, and it remains the most-studied area. The interest is easy to understand: conventional iron salts work, but a substantial proportion of people who take them experience nausea, constipation or abdominal pain, and stop. Lactoferrin offered the possibility of supporting iron status through a different route, and the trials that followed have been genuinely informative.

A different mechanism from iron salts

Ferrous sulfate delivers a large bolus of free iron to the gut. Lactoferrin does something quite different: it binds iron tightly, carries it to intestinal receptors, and appears to act on the body's own iron-regulation machinery. The central player is hepcidin, the hormone that governs how much dietary iron is absorbed and how much stored iron is released. Hepcidin is driven upward by inflammation, particularly by the cytokine interleukin-6, and when it is elevated, iron becomes locked in storage regardless of how much is consumed. This is why people with underlying inflammation often fail to respond to iron supplements.

Lactoferrin's anti-inflammatory activity is what makes this interesting: by lowering IL-6, it may help normalise iron regulation rather than simply flooding the system with more iron.

A further meta-analysis published in the European Journal of Obstetrics & Gynecology and Reproductive Biology examined lactoferrin against ferrous salts specifically in pregnancy and reached a similar conclusion on tolerability, and a clinical trial in children with inflammatory bowel disease, a population where inflammation-driven hepcidin elevation is a well-recognised obstacle to iron repletion, also reported positive results.

Understanding where the effect is strongest

Lactoferrin's position in the immune system is structural, not incidental. It is stored in the secondary granules of neutrophils and released at sites of infection, and it coats the mucosal surfaces that pathogens must cross first. It is best described as an immunomodulator rather than an immune stimulant: the research consistently shows it moderating excessive inflammatory signalling while supporting the mechanisms that clear pathogens.

The IL-6 result deserves emphasis, because it connects directly to the iron findings above and to the metabolic research below. IL-6 is a central driver of chronic low-grade inflammation, and it is the same signal that elevates hepcidin and blocks iron absorption. A single mechanism plausibly underlies effects in several apparently unrelated areas, which is precisely why lactoferrin is described in the literature as multifunctional.

More recent adult trials

Adult-specific research has expanded considerably since that review closed its search in December 2020. A randomised, double-blind, placebo-controlled trial published in Nutrients examined 200 mg/day of bovine lactoferrin over 12 weeks for the maintenance of respiratory and systemic physical condition in healthy adults. A 2026 randomised controlled trial in healthy older adults compared 600 mg/day and 200 mg/day against placebo over four weeks, reporting reduced systemic inflammation, enhanced antiviral responses and modulation of immune cell profiles. And a randomised, double-blind, controlled trial published in the Journal of Clinical Pharmacology in 2025 assessed two lactoferrin doses against an active control on immunological and safety parameters in healthy adults.

A 2026 randomised, double-blind, placebo-controlled trial in children aged 0–6 also found that lactoferrin combined with Bifidobacterium animalis subsp. lactis BB-12 over three months improved respiratory tract infection outcomes and modulated gut microbiome function, reinforcing the paediatric signal identified in the meta-analysis.

Explore this area further on our lactoferrin and immune defence page.

Lactoferrin's effect on gut bacteria follows directly from its chemistry, and it is unusually selective. Most pathogenic bacteria require free iron to grow; by binding iron tightly, lactoferrin makes the intestinal environment less hospitable to them. Beneficial Bifidobacterium species, by contrast, have low iron requirements and are largely unaffected, and there is evidence that lactoferrin actively supports their growth. The net result is a shift in the balance of the microbial community rather than the broad suppression an antibiotic produces.

Short-chain fatty acids are worth understanding here, because they are how a microbiome shift becomes a physiological one. When gut bacteria ferment fibre they produce butyrate, propionate and acetate. Butyrate is the primary fuel for the cells lining the colon and supports the integrity of the intestinal barrier. Changes in SCFA production are therefore a meaningful functional readout, not merely a change in the bacterial census.

Reviews of the prebiotic and modulatory evidence describe a consistent pattern across studies: support for beneficial genera, reduced colonisation by pathogenic organisms, and effects on intestinal barrier function. Research in infants has been particularly active, since lactoferrin is a major component of the milk that establishes the infant microbiome in the first place.

More detail on our lactoferrin for gut health page.

This is the oldest and most reproducible body of lactoferrin research. The laboratory evidence is extensive and consistent, and it operates through at least three distinct mechanisms, which is part of why microbial resistance to it is not readily observed.

Three separate mechanisms

1. Iron sequestration. Bacteria need free iron to replicate. Lactoferrin binds it with roughly 300 times the affinity of transferrin and retains it even at the low pH of an inflamed site, depriving pathogens of an essential nutrient. This is bacteriostatic: it restrains growth rather than killing outright.

2. Direct membrane disruption. Lactoferricin B, the peptide released from the N-terminal region during digestion, is strongly cationic and binds preferentially to the negatively charged membranes of bacteria over the largely neutral membranes of human cells. This selectivity is the basis of its favourable safety profile, and the activity is bactericidal and independent of iron.

3. Blocking viral attachment. Many viruses first anchor themselves to heparan sulfate proteoglycans on the cell surface, which concentrates them near their specific receptor. Lactoferrin binds those same heparan sulfate sites (via the positively charged N-terminal region, residues 17–41 in the bovine protein) and occupies the docking point before the virus can use it.

These are laboratory results and should be read as such: they explain a mechanism rather than demonstrate a clinical outcome. The most substantial human evidence in the antimicrobial category comes from a different setting entirely.

This is a useful illustration of how lactoferrin tends to perform in human research: less as a standalone intervention, more as something that improves the performance and tolerability of an existing one. That adjunctive pattern recurs across several of the areas on this page.

One of the more unexpected findings in the lactoferrin literature is its effect on fat tissue, unexpected because nothing about an iron-binding immune protein suggests it. The mechanism turned out to run through LRP1, one of the lactoferrin receptors described earlier, which sits in the lipolysis signalling pathway in mature adipocytes.

Two details make this trial more informative than its size alone suggests. The enteric coating was deliberate: the researchers reasoned that intestinal rather than gastric delivery was necessary, and a companion line of research on the same formulation reported the same visceral fat effect. And visceral fat area was measured by imaging rather than inferred from waist measurement, which is a considerably more precise endpoint.

The trial was small at 26 participants, and results of this kind warrant confirmation in larger groups, which is exactly what is now happening. Supporting work has extended the picture: preclinical studies found bovine lactoferrin reduced visceral fat and liver triglycerides; enteric lactoferrin attenuated diet-induced hypercholesterolaemia and atherosclerosis in a large-animal model; and a 2026 review in Frontiers in Nutrition examines lactoferrin as a multi-target nutritional modulator in type-2 diabetes, focusing on its anti-inflammatory activity and effects on the gut environment. Research has also begun to look at why individuals respond differently, including a study on the association between lactoferrin's anti-obesity effects and genetic variation.

See our lactoferrin for metabolic support page for more.

Skin research on lactoferrin rests on the same two properties that drive its effects elsewhere: moderation of inflammatory signalling, and influence on microbial balance. Acne involves both: the bacterium Cutibacterium acnes and an inflammatory response to it. That makes it a logical place to have looked first.

The sebum finding is the most mechanistically interesting result here. Reduced sebum production is not something an antimicrobial effect alone would explain: it points toward lactoferrin influencing the lipid metabolism of the sebaceous gland, which connects this work to the metabolic research above rather than leaving it as an isolated dermatological curiosity.

Separately, observational work has examined serum lactoferrin in people with mild versus severe acne in relation to disease duration, adding to the picture of lactoferrin's involvement in skin inflammation.

Read more on lactoferrin for clear skin and the skin microbiome and lactoferrin, or see how it works on acne from within.

Lactoferrin occurs naturally in saliva, alongside lysozyme and lactoperoxidase, as part of the mouth's own antimicrobial defence system. Oral health research has largely asked whether supplementing what is already present there produces measurable benefit, and because the mouth can be treated topically, these studies avoid the digestion question entirely.

A randomised controlled trial of lactoferrin-based oral care for periodontal health in pregnancy is currently recruiting, a population where periodontal inflammation carries particular significance and where lactoferrin's tolerability profile is an advantage.

More on our oral health and lactoferrin page.

These areas have smaller bodies of evidence than those above. They are included because the early results are genuinely encouraging and the mechanisms are plausible, and because a research page that showed only the well-trodden ground would be less useful.

Urinary tract and bladder

Lactoferrin is present in the urinary tract's own mucosal secretions, and the rationale here is specific: bovine lactoferrin inhibits the entry of several intracellular bacteria into host cells, which is relevant because recurrent urinary infection often involves bacteria that persist inside the bladder wall between episodes.

Both studies lack a placebo control, which means the results cannot yet be separated from natural fluctuation in symptoms, and the authors say as much. As a signal justifying properly controlled trials, though, they are strong. See lactoferrin for bladder and urinary support.

Bone

Laboratory work established that lactoferrin stimulates osteoblasts, the cells that build bone, promoting their proliferation and the expression of osteogenesis markers including alkaline phosphatase activity, while reducing oxidative stress.

Bone turnover markers are a surrogate endpoint: they indicate the direction of bone remodelling but are not the same as measured bone mineral density, which requires longer and larger trials to shift demonstrably.

Antioxidant activity

Lactoferrin's antioxidant contribution is largely a consequence of its iron binding. Free iron catalyses the Fenton reaction, generating hydroxyl radicals, among the most damaging reactive oxygen species in biology. By keeping iron bound and unavailable, lactoferrin prevents that reaction from occurring. This is preventive rather than scavenging chemistry: it stops radicals forming rather than neutralising them afterwards, and it is why lactoferrin's antioxidant behaviour is inseparable from its iron chemistry.

There is no official recommended intake for lactoferrin: it is a food component, not an essential nutrient with an established requirement. What exists instead is the record of what researchers have used, and what they observed at those amounts. The table below reports doses associated with findings in the studies covered on this page.

Duration matters as much as amount. Almost every trial reporting an effect ran for 8 to 12 weeks or longer (the review median was 12 weeks). Lactoferrin works through gradual processes (inflammatory signalling, microbial balance, iron regulation), and studies shorter than about four weeks rarely show much.

Lactoferrin's safety record is one of the strongest parts of its evidence base, helped considerably by the fact that humans have consumed it in milk throughout the species' existence, and that infants receive it in high concentration from birth.

Who should speak to a healthcare professional first

• Anyone with a diagnosed milk or dairy protein allergy, since lactoferrin is derived from cow's milk.
• Anyone with haemochromatosis or another iron-overload condition, given lactoferrin's interaction with iron metabolism.
• Anyone taking prescribed iron, or medication for an iron-related condition.
• Anyone who is pregnant or breastfeeding. Lactoferrin has been studied in pregnancy with encouraging results, but supplementation during pregnancy should always be supervised.
• Anyone taking immunosuppressive medication, or with an autoimmune condition, given lactoferrin's immunomodulatory activity.
• Parents considering lactoferrin for a child.

Lactoferrin is an active research field, not a closed one. Below is an honest account of the open questions: the areas where good scientists are still working, and where the next few years of publications are likely to sharpen the picture. We think this is the most useful section on the page.

Which populations benefit most

A recurring theme across the evidence is that lactoferrin's effects appear clearest where there is something for it to correct. Inflammation-driven iron dysregulation, disturbed microbial balance, elevated inflammatory markers: where these are present, effects are more consistently observed. Trials in healthy, well-nourished participants tend to show smaller changes, which makes sense for a regulatory protein, and is common to many nutritional interventions, but it means the question "who benefits most, and by how much" is still genuinely open.

Adult respiratory outcomes

The 2022 meta-analysis found a clear reduction in respiratory tract infection incidence in infants and children (OR 0.78) while the pooled adult estimate was neutral, largely because far fewer adult trials existed. The adult trials published since, including the 2026 study in older adults reporting enhanced antiviral responses and reduced systemic inflammation at 200 and 600 mg/day, are beginning to fill that gap, and the next synthesis of this literature should be considerably more informative than the last.

Large-scale work in preterm infants

Some of the most rigorous lactoferrin research has been conducted in neonatal intensive care, and it illustrates how the field self-corrects. A 2017 Cochrane review of six trials in 1,041 preterm infants found reductions in late-onset infection and necrotising enterocolitis, while noting that the studies were small and methodologically limited. The ELFIN trial, published in The Lancet, then tested the question at scale in 2,203 very preterm infants at 150 mg/kg/day, and did not find a reduction in late-onset infection, other morbidity or mortality in that population.

The accompanying MAGPIE mechanisms study examined the effect on gut microbiota in the same population, and separate work confirmed that bovine lactoferrin does not disrupt microbiota development in preterm infants receiving probiotics. Later analyses have suggested lactoferrin combined with probiotics may perform differently from lactoferrin alone. This is a hospital intervention in a highly specific and fragile population, at a dose and delivery route unlike adult supplementation, but it is a good example of the field asking hard questions of itself, and of why the strength-of-evidence labels on this page matter.

Formulation and delivery

Given that 62–79% of lactoferrin survives the stomach intact, how much difference does protecting the remainder make? Enteric coating, microencapsulation, liposomal delivery and PEGylation have all been studied, and the visceral fat trial used an enteric-coated preparation deliberately. Head-to-head comparisons of delivery formats at matched doses remain scarce, and would be valuable.

Iron saturation and source

Whether apo (iron-free) and holo (iron-saturated) lactoferrin differ meaningfully in their effects after oral intake is not fully resolved. Nor is the comparison between conventional milk-derived bovine lactoferrin and newer fermentation-derived and recombinant human forms. A 2026 trial has begun that comparison directly for microbiome outcomes, and structure-function work on fermentation-derived bovine lactoferrin produced in Komagataella phaffii is ongoing.

Long-term use

Most trials run 8 to 12 weeks; the longest ran 60. Lactoferrin's safety across that range is well documented, but data on multi-year use, particularly in children and older adults, is something researchers themselves identify as worth building.

What is bovine lactoferrin?

Bovine lactoferrin is an iron-binding glycoprotein purified from cow's milk. It is structurally very similar to the lactoferrin in human milk, around 69% identical in amino acid sequence, and shares its principal functions. In several laboratory comparisons, including antiviral assays, the bovine form has proven more potent than the human form.

Does this research apply to bioengineered or precision-fermented lactoferrin?

No, and this is worth being careful about. Every study on this page used bovine lactoferrin purified from cow's milk. Lactoferrin produced by precision fermentation, whether bioidentical human lactoferrin or a fermentation-derived bovine sequence, is a newer category with a much smaller clinical record, concentrated in studies published from 2024 onward and focused largely on safety, tolerability and early microbiome endpoints. Because lactoferrin is a glycoprotein and the organism producing it determines its sugar chains, findings from one form cannot be assumed to hold for another. See which lactoferrin this evidence applies to for the full comparison.

How much lactoferrin has been used in research?

Across 25 studies reviewed in Advances in Nutrition, doses ranged from 32.4 mg to 3 g per day, with a median of 225 mg/day. Adult trials cluster around 200–300 mg/day, and the review authors identified 200 mg/day as the dose associated with reduced systemic inflammation.

Does lactoferrin survive stomach acid?

Substantially, yes. Measured directly in healthy adults, gastric survival of intact bovine lactoferrin was 62–79%, with a large quantity reaching the small intestine intact. The portion that is broken down releases lactoferricin, an antimicrobial peptide with activity of its own.

How long does it take to see effects in studies?

Most trials reporting effects ran 8 to 12 weeks or longer; the median duration across the reviewed literature was 12 weeks. Some iron studies reported changes in haematological markers within 30 days. Studies shorter than about four weeks rarely show much.

Is lactoferrin safe?

It has a strong safety record. Bovine milk lactoferrin holds GRAS status in the United States, and studies using 1.5 g to 15 g per day for up to 42 weeks, including in vulnerable populations, have not found significant toxicity-related outcomes. It is a milk-derived protein, so it is unsuitable for anyone with a dairy allergy.

Can I take lactoferrin with iron supplements?

Several trials have studied them together, and prebiotic GOS with lactoferrin and iron supplements has been examined in a registered trial. Because lactoferrin interacts with iron metabolism, anyone taking prescribed iron should discuss this with the prescribing clinician first.

What is the difference between apo and holo lactoferrin?

Apolactoferrin is iron-free and retains full iron-binding capacity; holo-lactoferrin is iron-saturated and structurally more stable and more resistant to digestion. Most commercial bovine lactoferrin is around 10–20% saturated, meaning it is largely in the apo form.

Does lactoferrin help with iron deficiency?

The research is encouraging and nuanced. A meta-analysis of eight trials found a mean haemoglobin advantage of 1.18 g/dL over conventional iron supplementation, and trials in pregnancy report comparable haematological gains with markedly fewer digestive side effects. A larger 2026 trial in non-pregnant women with anaemia found ferrous sulfate more effective for raising haemoglobin in that setting. The consistent finding across the literature is better tolerability; the effect on iron status appears strongest where inflammation is interfering with iron regulation. Lactoferrin is not a replacement for iron therapy prescribed by a doctor.

Does lactoferrin affect the gut microbiome?

Human trials consistently show support for beneficial bacteria including Bifidobacterium and Lactobacillus, with effects on short-chain fatty acid production. The mechanism is selective: most pathogenic bacteria need free iron, which lactoferrin binds, while bifidobacteria have low iron requirements.

Is lactoferrin an antioxidant?

Indirectly, and effectively. By binding free iron it prevents the Fenton reaction, which generates hydroxyl radicals, so it stops those radicals forming rather than neutralising them after the fact.

Is lactoferrin suitable for vegetarians or vegans?

Bovine lactoferrin is derived from cow's milk. It is suitable for vegetarians who consume dairy, but not for vegans. Fermentation-derived and recombinant forms are an active area of development.

What is lactoferricin?

A 25-amino-acid peptide released from lactoferrin's N-terminal region when it meets pepsin in the stomach. It is strongly positively charged, binds preferentially to bacterial membranes over human cell membranes, and is a more potent direct antimicrobial than the intact protein.

Every study referenced above, with links to the source. Where available we link to PubMed, PubMed Central or the publisher's page for the peer-reviewed article.

1. Berthon BS, Williams LM, Williams EJ, Wood LG. Effect of Lactoferrin Supplementation on Inflammation, Immune Function, and Prevention of Respiratory Tract Infections in Humans: A Systematic Review and Meta-analysis. Adv Nutr. 2022. PMID 35481594 · Full text
2. Huda TM, et al. Bovine Lactoferrin Compared With Ferrous Sulfate for Treating Iron-Deficiency Anemia in Bangladeshi Women: A Randomized Controlled Trial. J Nutr. 2026. PMID 42302886 · Full text
3. The effectiveness of oral bovine lactoferrin compared to iron supplementation in patients with a low hemoglobin profile: a systematic review and meta-analysis of randomized clinical trials. BMC Nutr. 2023. DOI 10.1186/s40795-023-00818-6
4. Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: a meta-analysis of randomized trials. Eur J Obstet Gynecol Reprod Biol. 2017. PMID 29059584
5. Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial. Full text
6. Ono T, et al. Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr. 2010. Cambridge Core
7. Novel function of bovine lactoferrin in lipid metabolism: visceral fat reduction by enteric-coated lactoferrin. ScienceDirect
8. Kim J, et al. Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris. Nutrition. 2010. PMID 20692602
9. Nakano M, et al. Effect of tablets containing lactoferrin and lactoperoxidase on gingival health in adults: a randomized, double-blind, placebo-controlled clinical trial. J Periodontal Res. 2019. DOI 10.1111/jre.12679
10. Management of Gingival Bleeding in Periodontal Patients with Domiciliary Use of Toothpastes Containing Hyaluronic Acid, Lactoferrin, or Paraprobiotics: A Randomized Controlled Clinical Trial. Appl Sci. 2021. DOI 10.3390/app11188586
11. Sachdeva A, Nagpal J. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2009. PMID 19298339
12. Bharadwaj S, et al. Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women. Nutr Res. 2009. PMID 19172341
13. Troost FJ, et al. Gastric digestion of bovine lactoferrin in vivo in adults. J Nutr. 2001. PMID 11481401
14. Effect of bovine lactoferrin on recurrent urinary tract infections: in vitro and in vivo evidences. 2022. PMID 35768747
15. Lactoferrin in the treatment of interstitial cystitis: a retrospective pilot study. Biochem Cell Biol. 2024. DOI 10.1139/bcb-2024-0036
16. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. 2021. PMID 33560940
17. Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin. Front Mol Biosci. 2021. DOI 10.3389/fmolb.2021.607443
18. Griffiths J, et al. Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial (ELFIN). The Lancet. 2019. Full text · NIHR scientific summary
19. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews. Cochrane
20. Lactoferrin impact on gut microbiota in preterm infants with late-onset sepsis or necrotising enterocolitis: the MAGPIE mechanisms of action study. NIHR Journals Library
21. Grzywacz K, et al. Bovine Lactoferrin Supplementation Does Not Disrupt Microbiota Development in Preterm Infants Receiving Probiotics. J Pediatr Gastroenterol Nutr. 2020. DOI 10.1097/MPG.0000000000002734
22. Effects of Human Lactoferrin at Two Doses versus Bovine Lactoferrin on the Adult Gut Microbiome and Fecal Short-Chain Fatty Acids: A Randomized, Double-Blind Trial. J Diet Suppl. 2026. DOI 10.1080/19390211.2026.2673021
23. Bioavailability of a Novel Form of Microencapsulated Bovine Lactoferrin and Its Effect on Inflammatory Markers and the Gut Microbiome: A Pilot Study. Full text
24. Prebiotic and modulatory evidence of lactoferrin on gut health and function. ScienceDirect
25. Oral lactoferrin reduces systemic inflammation, enhances anti-viral responses and modulates immune cell profiles: a randomised controlled trial in healthy, older adults. 2026. Full text
26. Effects of Bovine Lactoferrin on the Maintenance of Respiratory and Systemic Physical Conditions in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2023. DOI 10.3390/nu15183959
27. Peterson RD, et al. A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults. J Clin Pharmacol. 2025. DOI 10.1177/10915818241293723
28. Lactoferrin combined with Bifidobacterium animalis subsp. lactis BB-12 improves respiratory tract infections and modulates gut microbiome function in children: a randomized, double-blind, placebo-controlled trial. PMID 42038244
29. The Multifaceted Roles of Bovine Lactoferrin: Molecular Structure, Isolation Methods, Analytical Characteristics, and Biological Properties. J Agric Food Chem. Full text
30. Influence of iron binding in the structural stability and cellular internalization of bovine lactoferrin. PMID 34632151
31. Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides. PMID 11908643
32. A lactoferrin-receptor, intelectin 1, affects uptake, sub-cellular localization and release of immunochemically detectable lactoferrin by intestinal epithelial Caco-2 cells. J Biochem. 2013. PMID 23921499
33. Role of LRP1 and ERK and cAMP Signaling Pathways in Lactoferrin-Induced Lipolysis in Mature Rat Adipocytes. PLOS ONE. DOI 10.1371/journal.pone.0141378
34. Lactoferrin: A glycoprotein that plays an active role in human health. Front Nutr. 2023. Full text
35. Lactoferrin as a multi-target nutritional modulator in type-2 diabetes. Front Nutr. 2026. DOI 10.3389/fnut.2026.1833440
36. Nutraceutical and Health-Promoting Potential of Lactoferrin, an Iron-Binding Protein in Human and Animal: Current Knowledge. Biol Trace Elem Res. DOI 10.1007/s12011-023-03658-4
37. A review of the safety evidence on recombinant human lactoferrin for use as a food ingredient. ScienceDirect
38. Structure and function of fermentation-derived bovine lactoferrin produced from Komagataella phaffii. Biochem Cell Biol. DOI 10.1139/bcb-2024-0105
39. Effect of in vitro simulated gastrointestinal digestion on the antibacterial properties of bovine lactoferrin. J Dairy Res. Cambridge Core
40. Formulation for Oral Delivery of Lactoferrin Based on Bovine Serum Albumin and Tannic Acid Multilayer Microcapsules. Sci Rep. DOI 10.1038/srep44159
41. Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice. PMID 23391533
42. Enteric lactoferrin attenuates the development of high-fat and high-cholesterol diet-induced hypercholesterolemia and atherosclerosis in Microminipigs. DOI 10.1080/09168451.2015.1091713
43. A study on the association between antiobesity effects of lactoferrin and genetic variations. ScienceDirect
44. A pilot study on serum lactoferrin in patients with mild versus severe acne in correlation with disease duration. DOI 10.4103/jewd.jewd_35_19
45. Lactoferrin-Based Oral Care for Periodontal Health in Pregnancy (trial registration). NCT07069140
46. Prebiotic GOS and Lactoferrin With Iron Supplements (trial registration). NCT03866837

How this review was compiled

Studies on this page were identified through searches of PubMed, PubMed Central, Cochrane and publisher databases for human research on bovine lactoferrin, with priority given to systematic reviews, meta-analyses and randomised controlled trials. Where a systematic review exists for a health area, it is used as the anchor and individual trials are presented in relation to it. Preclinical work is included only where it explains a mechanism, and is labelled as laboratory evidence.

Where findings differ between studies, both are reported along with the differences in population, dose, duration or comparator that may account for them. Doses, participant numbers and durations are stated for every trial so that readers can judge the weight of the evidence for themselves.

Last reviewed: September 2026. Review cycle: every six months, or sooner when a significant trial or systematic review is published.